CLINICAL IMPACT OF REPLACING MINNESOTA ANTILYMPHOCYTE GLOBULIN WITH ATGAM

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Transplantation

• Publication date

  1995-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00007890-199502000-00012PMID 7871567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG‐TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2

  1994cited by this paper
• Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.

  1994cited by this paper
• Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.

  1993cited by this paper
• THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTS

  1992cited by this paper
• The adverse impact of cyclosporine on serum lipids in renal transplant recipients.

  1991cited by this paper
• Early rejection: determining the fate of renal transplants.

  1991cited by this paper
• A prospective randomized comparison of antilymphoblast globulin versus antithymocyte globulin for cadaver kidney transplantation.

  1985cited by this paper
• Factors contributing for improved graft survival in recipients of kidney transplants.

  1983cited by this paper
• The nature of antiplatelet activity in antilymphoblast ALG--with special reference to cross-reacting antibody, immunochemical characterization, and Coombs' positive thrombocytopenia in ALG-treated renal recipients.

  1972cited by this paper
• Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man.

  1969cited by this paper
• The effect of heterologous antilymphocyte serum on the formation of H-2 antibody and the induction of allograft immunity.

  1969cited by this paper
• Studies of anti-lymphocyte globulins made from thoracic duct lymphocytes.

  1969cited by this paper
• Clinical use of antilymphoblast serum.

  1969cited by this paper
• Antiserum to lymphocytes: prolonged survival of canine renal allografts.

  1967cited by this paper
• An immunosupressive site of action of heterologous antilymphocyte serum.

  1967cited by this paper
• Nature and mode of action of antilymphocytic antiserum.

  1966cited by this paper

• Immunizations and infectious diseases in pediatric liver transplantation

  2008cites this paper
• Predicting long-term kidney graft survival: can new trials be performed?1,2

  2003cites this paper
• Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients.

  2001cites this paper
• Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease.

  2001cites this paper
• Immunosuppressive Drugs in Paediatric Liver Transplantation

  2001cites this paper
• Antithymocyte Globulin (Rabbit)

  2000cites this paper
• Significance of detecting epstein‐barr–specific sequences in the peripheral blood of asymptomatic pediatric liver transplant recipients

  2000cites this paper
• Epstein-Barr virus infection in sixty pediatric liver graft recipients: diagnosis of primary infection and virologic follow-up.

  1999cites this paper
• In vivo models for Epstein–Barr virus (EBV)‐associated B cell lymphoproliferative disease (BLPD)

  1999cites this paper
• Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.

  1999cites this paper
• The mother lode of liver transplantation, with particular reference to our new journal.

  1998cites this paper
• Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.

  1998cites this paper
• Tacrolimus for steroiD‐resistant liver rejection in children

  1998cites this paper
• Definitions of acute rejection and controlled clinical trials in the medical literature.

  1998cites this paper
• Tacrolimus for steroid-resistant liver rejection in children

  1998cites this paper
• Antilymphocyte induction therapy in cadaver renal transplantation: a retrospective, multicenter United Network for Organ Sharing Study.

  1997cites this paper
• Increased anti–Epstein—Barr virus antibodies in epidermotropic cutaneous T–cell lymphoma: a study of 64 patients

  1997cites this paper
• A Pharmacoeconomic Comparison of Antithymocyte Globulin and Muromonab CD3 Induction Therapy in Renal Transplant Recipients

  1997cites this paper
• Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era

  1996cites this paper
• Use of FK506 in pancreas transplantation

  1996cites this paper
• Use of FK 506 in pancreas transplantation.

  1996cites this paper
• A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation.

  1996cites this paper
• Antithymocyte Immunoglobulin in Severe Aplastic Anemia and Bone Marrow Transplantation

  1996cites this paper
• Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.

  1996cites this paper
• Combined pancreas-kidney transplants using quadruple immunosuppression therapy: a comparison between antilymphoblast and antithymocyte globulins.

  1995cites this paper